Lv3
390 积分 2021-09-02 加入
Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung
2天前
已完结
The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese lung large cell neuroendocrine carcinoma
2天前
已完结
The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese lung large cell neuroendocrine carcinoma
2天前
已完结
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)
3天前
求助中
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
4天前
已完结
An improved biomarker-guided adaptive patient enrichment design for oncology trials
7天前
已完结
Adaptive group‐sequential design with population enrichment in phase 3 randomized controlled trials with two binary co‐primary endpoints
7天前
已完结
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
21天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
21天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
21天前
已完结
皖公网安备34019202002308
